Original news and analysis on international IP policy
The issue of access to medicines is on the agenda at this week’s World Health Assembly (WHA) and public health advocates are seeking greater clarity and detail about the latest member state effort to address failings in the global system of research and development for medical products.
Negotiators worked late last night to reach some compromise on the intellectual property-related component of the emerging World Health Organization action plan on noncommunicable diseases.
Members of the World Health Organization this week have made noncommunicable diseases a top priority, and work on a draft resolution and action plan is being carried out by a drafting group that will report back later in the week.
World Health Organization Director General Margaret Chan today had strong messages for the opening day of the annual World Health Assembly: in these rocky times, public health work is a high ground that helps bring security and development, and if you are not doing all you can to advance global health for all, then you are part of the problem. She took a swipe at mega-industries – especially tobacco and junk food - that produce and market unhealthy products and spend heavily to work against effective public health policies.
On the eve of the 66th edition of the World Health Assembly, the World Health Editors Network (WHEN) and the Who’s There? Yes (WTY) convened for a conference on their new Journalism and Health Initiative. The conference, entitled, “Enter the stadium, democratise knowledge, bring it home,” focussed on increasing access and awareness of health policy and problems by the general public.
With just days before the UN World Health Assembly opens, member states once again face a packed agenda with key decisions to be taken on some highly-politicised public health and intellectual property matters, including how to move forward on the research and development draft resolution. The spotlight will also be on pandemic influenza preparedness, a resolution of size on noncommunicable diseases, the health-related Millennium Development Goals, and putting some reform decisions into practice.
While the World Health Organization’s latest health numbers show that great progress has been made in improving the health in low-income countries, significant inequalities remain between people living in the richest and poorest countries. Access to even the most basic medicines continues to be a major challenge due to high prices.
A panel of experts gathered at the Graduate Institute in Geneva last week discussed how to secure collective action to provide global public goods through research and development (R&D) for the particular public health needs of low and middle income countries.
Christopher J. Paun writes: Public-private partnerships (PPPs) are often used as a way of increasing public policy options by tapping into private sector resources. This occurs also in the field of intellectual property. There are several examples of Global PPPs against IP crimes - some more successful than others. Some prominent failures received a lot of attention when PPP activities were stopped following controversy about global IP policy.
As the World Health Organization kicks off a week devoted to the promotion of vaccines, newly published research has identified challenges, such as weak supply systems and information gaps, that need to be addressed to scale-up global vaccine coverage. But some observers say that more attention should be paid to the soaring costs of vaccines, starting with a mechanism to track prices.